医学
危险分层
肿瘤科
内科学
阶段(地层学)
临床试验
辅助治疗
队列
比例危险模型
结直肠癌
佐剂
预测模型
队列研究
分层(种子)
风险评估
生存分析
总体生存率
临床实习
签名(拓扑)
癌症
临床决策
梅德林
肿瘤分期
作者
Adel T. Aref,Mohashin Pathan,Rosemary Habib,Peter G. Hains,Stephanie Hui-Su Lim,Asim Anees,Li Ma,Judith A. Heads,Dongwei Wang,Clare Loudon,Duncan J. McLeod,Nicole Caixeiro,Zainab Noor,George E. Craft,Daniel Bucio-Noble,Jennifer M.S. Koh,Phillip James Robinson,Qing Zhong,Kavitha Gowrishankar,Kenneth P. Micklethwaite
标识
DOI:10.1158/1078-0432.ccr-25-3200
摘要
PURPOSE: Despite advances in colon cancer management, stage III disease lacks robust, clinically applicable prognostic biomarkers. We aimed to use proteomic profiling to provide a quantitative, tissue-based approach to improve recurrence risk stratification. EXPERIMENTAL DESIGN: We performed data-independent acquisition mass spectrometric proteomic analysis of tumor samples from three independent stage III colon cancer cohorts (n = 759). Differential protein expression between tumor and matched normal adjacent tissue was analyzed in the training cohort (cohort 1) using the limma package, and a univariate Cox model identified candidate biomarker proteins. A risk score based on the levels of six proteins (ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, and CKAP4) was developed using multivariate Cox regression in the training cohort (n = 175) and validated in two external cohorts (cohort 2, n = 386; cohort 3, n = 198). Kaplan-Meier and multivariate Cox regression analyses assessed the prognostic value of the score for recurrence. RESULTS: The six-protein risk score categorized patients in the training cohort as high- or low-risk for recurrence [hazard ratio (HR) 5.7, P < 0.001], and this was validated in the two separate cohorts (cohort 2: HR 1.8, P < 0.001; cohort 3: HR 1.8, P = 0.02). Integrating the proteomic score with clinical risk factors further enhanced prognostic accuracy (P < 0.001 in all three cohorts). The combined proteomic-clinical risk score consistently identified a subgroup of patients with very low recurrence risk across cohorts. CONCLUSIONS: The validated six-protein risk score improves prognostic stratification beyond standard clinical factors in stage III colon cancer, providing a robust framework for risk-adapted clinical investigation. Prospective, treatment-stratified clinical trials are warranted to determine whether this prognostic information can inform adjuvant therapy decision-making.
科研通智能强力驱动
Strongly Powered by AbleSci AI